U
15.66
-1.46 (-8.50%)
| Previous Close | 17.12 |
| Open | 17.07 |
| Volume | 2,800,485 |
| Avg. Volume (3M) | 2,514,713 |
| Market Cap | 975,487,424 |
| Price / Earnings (Forward) | 27.93 |
| Price / Sales | 70.48 |
| Price / Book | 5.59 |
| 52 Weeks Range | |
| Earnings Date | 2 Mar 2026 |
| Operating Margin (TTM) | -2,815.25% |
| Diluted EPS (TTM) | -4.38 |
| Quarterly Revenue Growth (YOY) | -81.50% |
| Total Debt/Equity (MRQ) | 1,522.46% |
| Current Ratio (MRQ) | 11.99 |
| Operating Cash Flow (TTM) | -166.25 M |
| Levered Free Cash Flow (TTM) | -122.89 M |
| Return on Assets (TTM) | -15.64% |
| Return on Equity (TTM) | -241.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | uniQure N.V. | Bullish | Bullish |
AIStockmoo Score
-0.4
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.38 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.09% |
| % Held by Institutions | 91.95% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (HC Wainwright & Co., 347.00%) | Buy |
| Median | 40.00 (155.43%) | |
| Low | 31.00 (Barclays, 97.96%) | Hold |
| Average | 45.40 (189.91%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 22.20 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Feb 2026 | 70.00 (347.00%) | Buy | 24.71 |
| Barclays | 28 Jan 2026 | 31.00 (97.96%) | Hold | 23.02 |
| Stifel | 11 Dec 2025 | 40.00 (155.43%) | Buy | 19.75 |
| Mizuho | 09 Dec 2025 | 33.00 (110.73%) | Buy | 20.78 |
| Chardan Capital | 04 Dec 2025 | 53.00 (238.44%) | Buy | 22.74 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Jan 2026 | Announcement | uniQure Announces Type A Meeting Scheduled with FDA |
| 04 Dec 2025 | Announcement | uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |